Russell Investments Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Russell Investments Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-78	Closed	-$7.95K	–	3663
2023 Q2	$7.95K	Sell	78 -46	-37%	-$4.35K	﹤0.01%	3014
2023 Q1	$11.3K	Sell	124 -6,018	-98%	-$353K	﹤0.01%	2868
2022 Q4	$233K	Buy	6,142 +994	+19%	+$34.2K	﹤0.01%	2533
2022 Q3	$129K	Buy	+5,148	New	+$143K	﹤0.01%	2627
2022 Q1	–	Sell	-42,089	Closed	-$1.11M	–	2994
2021 Q4	$1.11M	Buy	42,089 +874	+2%	+$67.6K	﹤0.01%	2099
2021 Q3	$4.14M	Buy	41,215 +5,898	+17%	+$691K	0.01%	1358
2021 Q2	$5M	Buy	+35,317	New	+$3.99M	0.01%	1350
2020 Q3	–	Sell	-5,787	Closed	-$902K	–	3278
2020 Q2	$902K	Buy	5,787 +4,264	+280%	+$648K	﹤0.01%	2117
2020 Q1	$219K	Sell	1,523 -3,663	-71%	-$707K	﹤0.01%	2518
2019 Q4	$1.06M	Buy	5,186 +2,689	+108%	+$491K	﹤0.01%	2068
2019 Q3	$200K	Buy	+2,497	New	+$212K	﹤0.01%	2612
2017 Q3	–	Sell	-8,012	Closed	-$254K	–	3022
2017 Q2	$254K	Buy	+8,012	New	+$197K	﹤0.01%	2635

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Russell Investments Group's RETA Position: Q3 2023 in Review

Russell Investments Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 78 shares — an estimated $7.95K sold.

Russell Investments Group first reported a position in RETA in Q2 2017 and held it in 12 quarters. The position peaked at $5M in Q2 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Russell Investments Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Russell Investments Group sold 78 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $7.95K.
Russell Investments Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2017 and held it in 12 quarters.
Russell Investments Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5M in Q2 2021.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Russell Investments Group's 13F filing for Q3 2023, filed 13 Nov 2023.